Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. (Q40389382)

20 September 2017

1 reference

title

Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. (English)

1 reference

20 September 2017

1 reference

L B Barradell

1

1 reference

PubMed ID

7514976

20 September 2017

H M Bryson

series ordinal

2

1 reference

20 September 2017

1 March 1994

1 reference

20 September 2017

1 reference

20 September 2017

47

1 reference

20 September 2017

471-505

1 reference

20 September 2017

3

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199447030-00007

20 September 2017

0 references

cites work

Affinities of PBPs of enterococci to cefepime and ampicillin

1 reference

12 December 2020

Effects of age and gender on pharmacokinetics of cefepime

1 reference

12 December 2020

Efficacy of BMY-28142 in experimental bacteremia and meningitis caused by Escherichia coli and group B streptococci

1 reference

12 December 2020

In vitro and in vivo activities of DQ-2556 and its mode of action

1 reference

12 December 2020

Cefepime as treatment for osteomyelitis and other severe bacterial infections

1 reference

12 December 2020

A clinical comparison of cefepime and metronidazole versus gentamicin and clindamycin in the antibiotic management of surgically treated advanced appendicitis.

1 reference

12 December 2020

In vitro studies of BMY-28142, a new broad-spectrum cephalosporin

1 reference

12 December 2020

Bactericidal activity of cefclidin (E1040) against Pseudomonas aeruginosa under conditions simulating plasma pharmacokinetics: lack of development of chromosomally-mediated resistance to beta-lactams

1 reference

12 December 2020

Immunomodulation by antibacterial agents. Is it clinically relevant?

1 reference

12 December 2020

In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin

1 reference

12 December 2020

Antibacterial activity of BMY-28142, a novel broad-spectrum cephalosporin.

1 reference

12 December 2020

Low-dosage cefepime as treatment for serious bacterial infections.

1 reference

12 December 2020

Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients

1 reference

12 December 2020

Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels

1 reference

12 December 2020

An evaluation of the penetration of cefepime into prostate tissue in patients undergoing elective prostatectomy

1 reference

12 December 2020

International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections

1 reference

12 December 2020

In vitro activity of Ro 09-1428 compared to other cephalosporins.

1 reference

12 December 2020

From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel

1 reference

12 December 2020

Pharmacokinetics of cefepime in subjects with renal insufficiency

1 reference

12 December 2020

Effects of beta-lactamase inducibility and derepression on the activity of cefpirome against gram-negative bacteria

1 reference

12 December 2020

Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics

1 reference

12 December 2020

Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis

1 reference

12 December 2020

Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

1 reference

12 December 2020

Susceptibility of new beta-lactams to the expanded-spectrum beta-lactamase CTX-1.

1 reference

12 December 2020

A non-comparative, multicentre study of cefepime in the treatment of serious bacterial infections

1 reference

12 December 2020

Disposition of the cephalosporin cefepime in normal and renally impaired subjects

1 reference

12 December 2020

Pharmacokinetics and tissue penetration of cefepime

1 reference

12 December 2020

Cefepime concentrations in bronchial mucosa and serum following a single 2 gram intravenous dose.

1 reference

12 December 2020

Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin

1 reference

12 December 2020

In vitro susceptibility of methicillin-resistant Staphylococcus aureus to imipenem and other antimicrobial agents.

1 reference

12 December 2020

A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae

1 reference

12 December 2020

Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses

1 reference

12 December 2020

Cefepime versus cefotaxime in the treatment of lower respiratory tract infections

1 reference

12 December 2020

Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects

1 reference

12 December 2020

Development of beta-lactam-resistant Enterobacter cloacae in mice.

1 reference

12 December 2020

In-vitro activity of BMY 28142, a new aminothiazolyl cephalosporin.

1 reference

12 December 2020

Cefepime for treatment of experimental chronic osteomyelitis due to Staphylococcus aureus

1 reference

12 December 2020

Pharmacokinetics of cefepime in patients with the sepsis syndrome

1 reference

12 December 2020

Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime

1 reference

12 December 2020

Pharmacokinetics of cefepime: a review.

1 reference

12 December 2020

In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin)

1 reference

12 December 2020

The influence of cefepime on opsonophagocytosis of bacteria.

1 reference

12 December 2020

A non-comparative study of the efficacy and tolerance of cefepime in combination with amikacin in the treatment of severe infections in patients in intensive care

1 reference

12 December 2020

Novel method for measurement of outer membrane permeability to new beta-lactams in intact Enterobacter cloacae cells

1 reference

12 December 2020

A comparative study of cefepime for chronic respiratory tract infections

1 reference

12 December 2020

Hydrolytic rate at low drug concentration as a limiting factor in resistance to newer cephalosporins.

1 reference

12 December 2020

Emergence of resistance during beta-lactam therapy of gram-negative infections. Bacterial mechanisms and medical responses

1 reference

12 December 2020

Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients

1 reference

12 December 2020

Comparative study of the effects of four cephalosporins against Escherichia coli in vitro and in vivo

1 reference

12 December 2020

In vitro activity of BRL 36650, a new penicillin

1 reference

12 December 2020

The antibiotic sensitivity of bacteria isolated from the blood of patients in St Thomas' Hospital, 1969-1988.

1 reference

12 December 2020

The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin

1 reference

12 December 2020

Species dependent variability in the susceptibility of coagulase-negative staphylococci to various antimicrobial agents.

1 reference

12 December 2020

High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine

1 reference

12 December 2020

Antibiotic susceptibility and beta-lactamase production in clinical isolates of Enterobacter spp.

1 reference

12 December 2020

A randomized study of cefepime versus the combination of gentamicin and mezlocillin as an adjunct to surgical treatment in patients with acute cholecystitis.

1 reference

12 December 2020

Comparative in vitro activity of cefpirome and cefepime, two new cephalosporins

1 reference

12 December 2020

In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum

1 reference

12 December 2020

Antibacterial Properties of Investigational, New, and Commonly Used Antibiotics against Isolates of <i>Pseudomonas cepacia </i>in Michigan

1 reference

12 December 2020

Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329

1 reference

12 December 2020

Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime

1 reference

12 December 2020

Comparative in vitro activities of ampicillin, BMY 28142, and imipenem against Mycobacterium avium complex

1 reference

12 December 2020

In vitro activity of cefprozil (BMY 28100) and cefepime (BMY 28142) against Streptococcus pneumoniae, Branhamella catarrhalis, and Haemophilus influenzae, and provisional interpretive criteria for disk diffusion and dilution susceptibility tests wit

1 reference

12 December 2020

Selection and characterization of cefepime-resistant gram-negative bacteria.

1 reference

12 December 2020

Reevaluation of the factors involved in the efficacy of new beta-lactams against Enterobacter cloacae

1 reference

12 December 2020

New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits

1 reference

12 December 2020

In-vitro activity of cefepime and other antimicrobials: survey of European isolates

1 reference

12 December 2020

In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents

1 reference

12 December 2020

Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime

1 reference

12 December 2020

Pharmacokinetics of cefepime in cystic fibrosis patients

1 reference

12 December 2020

A comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections

1 reference

12 December 2020

Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases

1 reference

12 December 2020

A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia

1 reference

12 December 2020

Enhanced phagocytosis of encapsulated Escherichia coli strains after exposure to sub-MICs of antibiotics is correlated to changes of the bacterial cell surface

1 reference

12 December 2020

Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. The Canadian Antimicrobial Resistance Study Group

1 reference

12 December 2020

Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins

1 reference

12 December 2020

Open trial of cefepime (BMY 28142) for infections in hospitalized patients

1 reference

12 December 2020

A comparative study of cefepime for bacterial pneumonia

1 reference

12 December 2020

Activity of newer antimicrobial agents against Aeromonas hydrophila

1 reference

12 December 2020

In vitro susceptibility of Acinetobacter species to various antimicrobial agents

1 reference

12 December 2020

Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment

1 reference

12 December 2020

Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics

1 reference

12 December 2020

In-vitro susceptibility of Pseudomonas species to fifteen antimicrobial agents

1 reference

12 December 2020

Cefepime for infections of the biliary tract

1 reference

12 December 2020

In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin

1 reference

12 December 2020

In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosa

1 reference

12 December 2020

Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model

1 reference

12 December 2020

Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers

1 reference

12 December 2020

Activity of cefepime and other beta-lactam antibiotics against permeability mutants of Escherichia coli and Klebsiella pneumoniae.

1 reference

12 December 2020

Pharmacokinetics of cefepime in patients with respiratory tract infections

1 reference

12 December 2020

In-vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142 and other antibiotics against nosocomially important isolates from cancer patients

1 reference

12 December 2020

Comparative in vitro antibacterial activity of the new carbapenem meropenem (SM-7338).

1 reference

12 December 2020

Microbial resistance to newer generation beta-lactam antibiotics: clinical and laboratory implications

1 reference

12 December 2020

Therapeutic studies of cefepime (BMY 28142) in murine meningitis and pharmacokinetics in neonatal rats

1 reference

12 December 2020

Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations

1 reference

12 December 2020

Cefepime: the next generation?

1 reference

12 December 2020

Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin

1 reference

12 December 2020

Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents

1 reference

12 December 2020

In vitro activity of BMY-28142, a new cephalosporin

1 reference

12 December 2020

Cefepime clinical pharmacokinetics

1 reference

12 December 2020

Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects

1 reference

12 December 2020

Susceptibility of group B and group G streptococci to newer antimicrobial agents

1 reference

12 December 2020

Cephalosporinase interactions and antimicrobial activity of BMY-28142, ceftazidime and cefotaxime.

1 reference

12 December 2020

HR 810 and BMY-28142, two new cephalosporins with broad-spectrum activity: an in-vitro comparison with other beta-lactam antibiotics

1 reference

12 December 2020

The effect of cefepime on some immune parameters in vitro: lack of interference with mitogen-induced lymphoproliferation, immunoglobulin synthesis, IFN-gamma and IL-2 secretion and IL-2 receptor expression

1 reference

12 December 2020

Dose finding study of cefepime for chronic respiratory infections

1 reference

12 December 2020

Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid

1 reference

12 December 2020

In-vitro activity of cefepime against bacterial pathogens from hospitalized patients

1 reference

12 December 2020

Outer membrane barrier as a mechanism of antimicrobial resistance

1 reference

12 December 2020

In vitro activity of cefquinome, a new cephalosporin, compared with other cephalosporin antibiotics

1 reference

12 December 2020

In vitro activity of cefepime, a new parenteral cephalosporin, against recent European blood isolates and in comparison with piperacillin/tazobactam

1 reference

12 December 2020

Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis

1 reference

12 December 2020

Randomized comparative study of cefepime and cefotaxime in the treatment of acute obstetric and gynaecological infections

1 reference

12 December 2020

Influence of subinhibitory concentrations of cephalosporins on the serum sensitivity of Pseudomonas aeruginosa

1 reference

12 December 2020

beta-Lactamases and beta-lactam resistance in Escherichia coli

1 reference

12 December 2020

beta-Lactam resistance amongst Enterobacter species

1 reference

12 December 2020

Analysis of cefepime tissue penetration into human appendix

1 reference

12 December 2020

Mechanisms of Bacterial Resistance to Antimicrobial Agents, with Particular Reference to Cefotaxime and Other β-Lactam Compounds

1 reference

12 December 2020

Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects

1 reference

12 December 2020

Cefepime pharmacokinetics in cystic fibrosis.

1 reference

12 December 2020

Lack of pharmacokinetic interaction between cefepime and amikacin in humans

1 reference

12 December 2020

Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins

1 reference

12 December 2020

10.2165/00003495-199447030-00007

Identifiers

DOI

1 reference

PubMed ID

7514976

Dimensions Publication ID

20 September 2017

0 references

1 reference

PubMed ID

7514976